Treatment of Latent Tuberculosis Infection

Primary Regimen: Isoniazid Monotherapy

The Centers for Disease Control and Prevention recommends isoniazid 300 mg daily for 9 months as the preferred treatment for latent TB infection in adults, providing maximal benefit with proven efficacy in preventing progression to active disease 1, 2
A 6-month isoniazid regimen is an acceptable alternative that provides substantial protection and may be preferred from a cost-effectiveness standpoint in certain situations 1
For individuals with HIV infection or radiographic evidence of prior TB, the 9-month duration is strongly recommended over 6 months 1, 2
Intermittent dosing (isoniazid 900 mg twice weekly) may be used but must be administered as directly observed therapy (DOT) 1

The American Thoracic Society recommends rifampin 600 mg daily for 4 months as an alternative regimen for patients who cannot tolerate isoniazid or pyrazinamide, based on efficacy in tuberculin-positive persons with silicosis and those exposed to isoniazid-resistant TB 1, 2
Rifampin 600 mg plus pyrazinamide daily for 2 months is another alternative regimen, previously recommended based on trials showing similar safety and efficacy to 12-month isoniazid in HIV-infected persons 1, 2

For children and adolescents, isoniazid 10-15 mg/kg (maximum 300 mg) daily for 9 months is the recommended regimen 1, 2
For HIV-infected persons, the 9-month isoniazid regimen is strongly preferred over 6 months 1, 2, 3
For pregnant women, isoniazid 300 mg daily or twice weekly for 9 or 6 months is recommended, and therapy should not be delayed based on pregnancy alone, even during the first trimester, for those at high risk for progression 1, 2

For individuals exposed to isoniazid-resistant, rifampin-susceptible TB, rifampin 600 mg plus pyrazinamide daily for 2 months is recommended 1, 2
For individuals exposed to multidrug-resistant (MDR) TB, pyrazinamide plus ethambutol or pyrazinamide plus a fluoroquinolone (levofloxacin or ofloxacin) for 6-12 months is recommended 1, 2

Before initiating LTBI treatment, active TB disease must be ruled out through history and physical examination, chest radiography, and bacteriologic studies when indicated 1, 2

Monthly follow-up evaluations are recommended for patients receiving isoniazid alone or rifampin alone, and evaluations at 2, 4, and 8 weeks for patients receiving rifampin plus pyrazinamide 1, 2
Baseline liver function tests are not routinely indicated for all patients, but are recommended for HIV-infected patients, pregnant women, and persons with chronic liver disease history or at risk for chronic liver disease 1, 2

Active hepatitis and end-stage liver disease are relative contraindications to isoniazid or pyrazinamide for LTBI treatment 2
Rifampin has significant drug interactions, including with oral contraceptives, anticoagulants, and antiretroviral drugs, requiring careful medication review 3

In patients receiving rifampin, there is no clinically significant interaction with ACE inhibitors, allowing standard dosing without adjustment【4】.
Lisinopril is primarily eliminated by the kidneys and is not metabolized by CYP450 enzymes, rendering it unaffected by rifampin’s enzyme‑inducing properties【5】.

Although rifampin can induce CYP3A4 and theoretically lower amlodipine concentrations, clinical studies show that this effect rarely impacts blood‑pressure control, so routine dose changes are unnecessary【6】.
Routine blood‑pressure monitoring remains appropriate, but pre‑emptive amlodipine dose reduction is not required when initiating rifampin therapy【7】.

The recommended standard dose of rifampin is 600 mg daily for individuals weighing more than 50 kg and 450 mg daily for those weighing less than 50 kg, to be used as part of the conventional four‑drug regimen【4】【8】.
No dose modification of rifampin is needed based on concurrent use of ACE inhibitors or calcium‑channel blockers【4】【8】.

In patients receiving warfarin (e.g., with a mechanical heart valve) who require rifampin‑containing anti‑tuberculosis therapy, discontinuation of rifampin is not recommended; instead, the warfarin dose should be increased to maintain therapeutic anticoagulation, because rifampin induces hepatic enzymes that lower warfarin’s effect. This approach avoids the risk of subtherapeutic anticoagulation while preserving essential TB treatment. 9